Moreover, the frequency of EGFR 19-Del mutations (22.54%) and EGFR 21 L858R mutations (24.25%) in patients with adenocarcinoma was higher than in patients with other types of NSCLC (all P< 0.001) (Table 5). This evidence concerns the gene EGFR and adenocarcinoma.